Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse and / or Refractory Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT05519085
What this trial is testing

Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Celgene 810
Very early researchLooking for participantsNCT06045091
What this trial is testing

To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL

Who this might be right for
Multiple MyelomaPlasma Cell Leukemia
Hrain Biotechnology Co., Ltd. 18
Not applicableNo Longer AvailableNCT00063791
What this trial is testing

Assess Two Different Strategies of Combining Dexamethasone and VELCADE

Who this might be right for
Multiple Myeloma
Millennium Pharmaceuticals, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT07523555
What this trial is testing

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLLRelapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia+4 more
Beijing Biotech 96
Early research (Phase 1)Looking for participantsNCT06153251
What this trial is testing

Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 187
Early research (Phase 1)Active Not RecruitingNCT06425991
What this trial is testing

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 108
Testing effectiveness (Phase 2)Study completedNCT03860038
What this trial is testing

TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseRefractory Multiple Myeloma
TJ Biopharma Co., Ltd. 113
Not applicableApproved For MarketingNCT01632826
What this trial is testing

Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene
Large-scale testing (Phase 3)Active Not RecruitingNCT05028348
What this trial is testing

Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Who this might be right for
Multiple Myeloma
European Myeloma Network B.V. 117
Testing effectiveness (Phase 2)UnknownNCT04287855
What this trial is testing

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Poitiers University Hospital 82
Testing effectiveness (Phase 2)Ended earlyNCT00441168
What this trial is testing

Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen-Cilag International NV 30
Large-scale testing (Phase 3)Study completedNCT01239797
What this trial is testing

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Who this might be right for
LymphomaMultiple Myeloma
Bristol-Myers Squibb 646
Early research (Phase 1)Ended earlyNCT01999335
What this trial is testing

Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Amgen 33
Early research (Phase 1)Study completedNCT02955550
What this trial is testing

A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
Celularity Incorporated 15
Early research (Phase 1)Looking for participantsNCT07003568
What this trial is testing

Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Beijing GoBroad Hospital 18
Not applicableStudy completedNCT02075996
What this trial is testing

Non-interventional Study With Pomalidomide (Imnovid®)

Who this might be right for
Multiple Myeloma
iOMEDICO AG 151
Post-approval studies (Phase 4)WithdrawnNCT05183139
What this trial is testing

In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Takeda
Testing effectiveness (Phase 2)Ended earlyNCT01177683
What this trial is testing

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Who this might be right for
Multiple Myeloma
Sherif Farag, MB, BS 32
Testing effectiveness (Phase 2)Study completedNCT00618345
What this trial is testing

Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Mayo Clinic 35
Not applicableStudy completedNCT06163040
What this trial is testing

Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb 7
Next Page